CytomX Therapeutics Inc (CTMX)
0.9828
-0.04
(-3.65%)
USD |
NASDAQ |
Jan 08, 16:00
0.9801
0.00 (0.00%)
After-Hours: 20:00
CytomX Therapeutics SG&A Expense (Quarterly): 7.953M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
Spero Therapeutics Inc | 5.198M |
Castle Biosciences Inc | 50.50M |
Verastem Inc | 12.28M |
Arcutis Biotherapeutics Inc | 58.82M |
NovaBay Pharmaceuticals Inc | 2.65M |